CPT-11 in human colon-cancer cell lines and xenograft: Characterization of cellular sensitivity determinants

International Journal of Cancer

Volumn 70, Issue 3, 1997, Pages 335-340

  Jansen, Willy J M ^a   Zwart, Bas ^a   Hulscher, Saskia T M ^a   Giaccone, Giuseppe ^a   Pinedo, Herbert M ^a   Boven, Epie ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CPT 11 METABOLITE; DNA TOPOISOMERASE; IRINOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031046059     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.0.CO;2-E     Document Type: Article

References (27)

1. ABIGERGES, D., CHABOT, G.G., ARMAND, J.P., HERAIT, P., GOUYETTE, A. and GANDIA, D., Phase-I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. clin. Oncol., 13, 210-221 (1995).
2. BOVEN, E., WINOGRAD, B., FODSTAD, O., LOBBEZOO, M.W. and PINEDO, H.M., Preclinical phase-II studies in human tumor lines: a European multicenter study. Europ. J. Cancer clin. Oncol., 24, 567-573 (1988).
3. CHANG, J-Y., DETHLEFSEN, L.A., BARLEY, L.R., ZHOU, B. and CHENG, Y., Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol, 43, 2443-2452 (1992).
4. CREEMERS, G.J., LUND, B. and VERWEIJ, J., Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20, 73-96 (1994).
5. FUJIMORI, A., HARKER, W.G., KOHLHAGEN, G., HOKI, Y. and POMMIER, Y., Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55, 1339-1346 (1995).
6. GALLO, R.C., WHANG-PHENG, J. and ADAMSON, R.H., Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. nat. Cancer Inst., 48, 1722-1726 (1971).
7. GIACCONE, G., VAN ARK-OTTE, J., SCAGLIOTTI, G., CAPRANICO, G., VAN DER VALK, P., RUBIO, G., DALESIO, O., LOPEZ, R., ZUNINO, F., WALBOOMERS, J. and PINEDO, H.M., Differential expression of DNA topoisomerases in non-small-cell lung cancer and normal lung. Biochim. biophys. Acta, 1264, 337-346 (1995).
8. GOLDWASSER, F., BAE, I., VALENTI, M., TORRES, K. and POMMIER, Y., Topoisomerase-I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55, 2116-2121 (1995).
9. HECK, M.M.S., HITTELMAN, W.N. and EARNSHAW, W.C., Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. Proc. nat. Acad. Sci. (Wash.), 85, 1086-1090 (1988).
10. HOUGHTON, P.J., CHESHIRE, P.J., HALLMAN, J.D., LUTZ, L., FRIEDMAN, H.S., DANKS, M.K. and HOUGHTON, J.A., Efficacy of topoisomerase-I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36, 393-103 (1995).
11. JANSEN, W.J.M., PINEDO, H.M., VAN DER WILT, C.L., FELLER, N., BAMBERGER, U. and BOVEN, E., The influence of BIBW22BS. a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts. Europ. J. Cancer, 31, 2313-2319 (1995).
12. JUAN, C.C., HWANG, J., LIU, A.A., WHANG-PENG, J., KNUTSEN, T., HUEBNER, K., CROCE, C.M., ZHANG, H., WANG, J.C. and LIU, L.F., Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20ql2-13.2. Proc. nat. Acad. Sci. (Wash.), 85, 8910-8913 (1988).
13. KANZAWA, F., SUGIMOTO, Y., MINATO, K., KASAHARA, K., BUNCO, M., NAKAGAWA, K., FUJIWARA, Y., LIU, L.F. and SAIJO, N., Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-smallcell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
14. KAWATO, Y., FURUTA, T., AONUMA, M., YASUOKA, M., YOKOKURA, T. and MATSUMOTO, K., Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192-198 (1991).
15. LIU, L.F. and MILLER, K.G., Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. nat. Acad. Sci. (Wash.), 78, 3487-3491 (1981).
16. MATTERN, M.R., HOFMANN, G.A., POLSKY, R.M., FUNK, L.R., MCCABE, F.L. and JOHNSON, R.K., In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol. Res., 5, 467-474 (1993).
17. NEGRI, C., CHIESA, R., CERINO, A., BESTAGNO, M., SALA, C., ZINI, M., MARALDI, N.M. and ASTALDI RICOTTI, G.C.B., Monclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp. Cell Res., 200, 452-459 (1992).
18. OGASAWARA, H., NISHIO, K., KANZAWA, F., LEE, Y-S., FUNAYAMA, Y., OHIRA, T., KURAISHI, Y., ISOGAI, Y. and SAIJO, N., Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jap. J. Cancer Res., 86, 124-129 (1995).
19. PEREGO, P., CAPRANICO, G., SUPINO, R. and ZUNINO, F., Topoisomerase-I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anti-Cancer Drugs, 4, 645-649 (1994).
20. RIVORY, L.P. and ROBERT, J., Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol. Ther., 68, 269-296 (1995).
21. ROTHENBERG, M.L., KUHN, J.G., BURRIS, H.A., NELSON, J., ECKARDT, J.R., TRISTAN-MORALES, M., HILSENBECK, S.G., WEISS, G.R., SMITH, L.S., RODRIGUEZ, G.I., ROCK, M.K. and VON HOFF, D.D., Phase-I and pharmacokinetic trial of weekly CPT-11. J. clin. Oncol, 11, 2194-2204 (1993).
22. RUBIN, E., PANTAZIS, P., BHARTI, A., TOPPMEYER, D., GIOVANELLA, B. and KUFE, D., Identification of a mutant topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. biol. Chem., 269, 2433-2439 (1994).
23. SLICHENMYER, W.J., ROWINSKY, E.K., DONEHOWER, R.C. and KAUFMANN, S.H., The current status of camptothecin analogues as antitumor agents. J. nat. Cancer Inst., 85, 271-291 (1993).
24. SUGIMOTO, Y., TSUKAHARA, S., OH-HARA, T., ISOE, T. and TSURUO, T., Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
25. TANIZAWA, A., KOHN, K.W., KOHLHAGEN, G., LETEURTRE, F. and POMMIER, Y., Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34, 7200-7206 (1995).
26. TSUJI, K., KANEDA, N., KADO, K., YOKOKURA, T., YOSHIMOTO, T. and TSURU, D., CPT-11 converting enzyme from rat serum: purification and some properties. J. pharmacobiol. Dyn., 14, 341-349 (1991).
27. WOESSNER, R.D., ENG, W.K., HOFMANN, G.A., RIEMAN, D.J., MCCABE, F.L., HERTZBERG, R.P., MATTERN, M.R., TAN, K.B. and JOHNSON, R.K., Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res., 4, 481-188 (1992).